Ubiquitination and degradation of the thrombopoietin receptor c-Mpl

Blood

Volumn 115, Issue 6, 2010, Pages 1254-1263

  Saur, Sebastian J ^a   Sangkhae, Veena ^a   Geddis, Amy E ^a   Kaushansky, Kenneth ^a   Hitchcock, Ian S ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; C MPL PROTEIN; CBL PROTEIN; LYSINE; PROTEASOME; SHORT HAIRPIN RNA; THROMBOPOIETIN; THROMBOPOIETIN RECEPTOR; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; CBL PROTEIN, HUMAN; MESSENGER RNA; MPL PROTEIN, HUMAN; SMALL INTERFERING RNA; UBIQUITIN; UBIQUITIN PROTEIN LIGASE;

ANIMAL CELL; ARTICLE; CELL DIFFERENTIATION; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; GENE OVEREXPRESSION; HEMATOPOIETIC STEM CELL; LYSOSOME; MEGAKARYOCYTE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; SITE DIRECTED MUTAGENESIS; UBIQUITINATION; ANIMAL; CELL CULTURE; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; HUMAN; IMMUNOBLOTTING; IMMUNOPRECIPITATION; METABOLISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THROMBOCYTE; WESTERN BLOTTING;

ANIMALS; BLOOD PLATELETS; BLOTTING, WESTERN; CELL DIFFERENTIATION; CELL PROLIFERATION; CELLS, CULTURED; HEMATOPOIETIC STEM CELLS; HUMANS; IMMUNOBLOTTING; IMMUNOPRECIPITATION; LYSINE; MEGAKARYOCYTES; MICE; MUTAGENESIS, SITE-DIRECTED; PROTO-ONCOGENE PROTEINS C-CBL; RECEPTORS, THROMBOPOIETIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; THROMBOPOIETIN; UBIQUITIN; UBIQUITIN-PROTEIN LIGASES; UBIQUITINATION;

EID: 77949525475     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-06-227033     Document Type: Article

References (42)

1. Kaushansky K, Drachman JG. The molecular and cellular biology of thrombopoietin: the primary regulator of platelet production. Oncogene. 2002; 21(21):3359-3367. (Pubitemid 34587708)
2. Kaushansky K. Thrombopoietin and the hematopoietic stem cell. Ann N Y Acad Sci. 2005;1044:139-141.
3. Fox N, Priestley G, Papayannopoulou T, Kaushansky K. Thrombopoietin expands hematopoietic stem cells after transplantation. J Clin Invest. 2002;110(3):389-394.
4. Geddis AE. Congenital amegakaryocytic thrombocytopenia and thrombocytopenia with absent radii. Hematol Oncol Clin North Am. 2009;23(2):321-331.
5. Steinberg O, Gilad G, Dgany O, et al. Congenital amegakaryocytic thrombocytopenia-3 novel c-MPL mutations and their phenotypic correlations. J Pediatr Hematol Oncol. 2007;29(12):822-825. (Pubitemid 350307703)
6. Kaushansky K. On the molecular origins of the chronic myeloproliferative disorders: it all makes sense. Blood. 2005;105(11):4187-4190. (Pubitemid 40720761)
7. Lasho TL, Pardanani A, McClure RF, et al. Concurrent MPL515 and JAK2V617F mutations in myelofibrosis: chronology of clonal emergence and changes in mutant allele burden over time. Br J Haematol. 2006;135(5):683-687. (Pubitemid 44674079)
8. Pardanani AD, Levine RL, Lasho T, et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood. 2006;108(10):3472-3476.
9. Hitchcock IS, Fox NE, Prevost N, Sear K, Shattil SJ, Kaushansky K. Roles of focal adhesion kinase (FAK) in megakaryopoiesis and platelet function: studies using a megakaryocyte lineage specific FAK knockout. Blood. 2008;111(2):596-604.
10. Lannutti BJ, Minear J, Blake N, Drachman JG. Increased megakaryocytopoiesis in Lyn-deficient mice. Oncogene. 2006;25(23):3316-3324.
11. Tong W, Lodish HF. Lnk inhibits Tpo-mpl signaling and Tpo-mediated megakaryocytopoiesis. J Exp Med. 2004;200(5):569-580. (Pubitemid 39258306)
12. Wang Q, Miyakawa Y, Fox N, Kaushansky K. Interferon-alpha directly represses megakaryopoiesis by inhibiting thrombopoietin-induced signaling through induction of SOCS-1. Blood. 2000;96(6):2093-2099.
13. Hitchcock IS, Chen MM, King JR, Kaushansky K. YRRL motifs in the cytoplasmic domain of the thrombopoietin receptor regulate receptor internalization and degradation. Blood. 2008;112(6): 2222-2231.
14. Shenoy SK. Seven-transmembrane receptors and ubiquitination. Circ Res. 2007;100(8):1142-1154.
15. Sigismund S, Polo S, Di Fiore PP. Signaling through monoubiquitination. Curr Top Microbiol Immunol. 2004;286:149-185.
16. Marmor MD, Yarden Y. Role of protein ubiquitylation in regulating endocytosis of receptor tyrosine kinases. Oncogene. 2004;23(11):2057-2070. (Pubitemid 38496735)
17. Joazeiro CA, Wing SS, Huang H, Leverson JD, Hunter T, Liu YC. The tyrosine kinase negative regulator c-Cbl as a RING-type, E2-dependent ubiquitin-protein ligase. Science. 1999; 286(5438):309-312. (Pubitemid 29484697)
18. Klapper LN, Glathe S, Vaisman N, et al. The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors. Proc Natl Acad Sci U S A. 1999;96(9):4995-5000. (Pubitemid 29214524)
19. Lee PS, Wang Y, Dominguez MG, et al. The Cbl protooncoprotein stimulates CSF-1 receptor multiubiquitination and endocytosis, and attenuates macrophage proliferation. EMBO J. 1999;18(13): 3616-3628. (Pubitemid 29308842)
20. Miyake S, Lupher ML Jr, Druker B, Band H. The tyrosine kinase regulator Cbl enhances the ubiquitination and degradation of the platelet-derived growth factor receptor alpha. Proc Natl Acad Sci U S A. 1998;95(14):7927-7932. (Pubitemid 28326043)
21. Peschard P, Fournier TM, Lamorte L, et al. Mutation of the c-Cbl TKB domain binding site on the Met receptor tyrosine kinase converts it into a transforming protein. Mol Cell. 2001;8(5):995-1004. (Pubitemid 34031802)
22. Levkowitz G, Waterman H, Ettenberg SA, et al. Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-Cbl/Sli-1. Mol Cell. 1999;4(6):1029-1040. (Pubitemid 30054908)
23. Waterman H, Katz M, Rubin C, et al. A mutant EGF-receptor defective in ubiquitylation and endocytosis unveils a role for Grb2 in negative signaling. EMBO J. 2002;21(3):303-313. (Pubitemid 34137292)
24. Fox NE, Chen R, Hitchcock I, Keates-Baleeiro J, Frangoul H, Geddis AE. Compound heterozygous c-Mpl mutations in a child with congenital amegakaryocytic thrombocytopenia: functional characterization and a review of the literature. Exp Hematol. 2009;37(4):495-503.
25. Marshall CJ. Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell. 1995;80(2):179-185.
26. Murphy LO, Smith S, Chen RH, Fingar DC, Blenis J. Molecular interpretation of ERK signal duration by immediate early gene products. Nat Cell Biol. 2002;4(8):556-564.
27. Ciesielski MJ, Fenstermaker RA. Oncogenic epidermal growth factor receptor mutants with tandem duplication: gene structure and effects on receptor function. Oncogene. 2000;19(6):810-820.
28. Hunter MG, Avalos BR. Deletion of a critical internalization domain in the G-CSFR in acute myelogenous leukemia preceded by severe congenital neutropenia. Blood. 1999;93(2):440-446.
29. Schmidt MH, Furnari FB, Cavenee WK, Bogler O. Epidermal growth factor receptor signaling intensity determines intracellular protein interactions, ubiquitination, and internalization. Proc Natl Acad Sci U S A. 2003;100(11):6505-6510. (Pubitemid 36666611)
30. Ward AC, van Aesch YM, Schelen AM, Touw IP. Defective internalization and sustained activation of truncated granulocyte colony-stimulating factor receptor found in severe congenital neutropenia/ acute myeloid leukemia. Blood. 1999;93(2):447-458.
31. Walrafen P, Verdier F, Kadri Z, Chretien S, Lacombe C, Mayeux P. Both proteasomes and lysosomes degrade the activated erythropoietin receptor. Blood. 2005;105(2):600-608. (Pubitemid 40070742)
32. Tanaka Y, Tanaka N, Saeki Y, et al. c-Cbl-dependent monoubiquitination and lysosomal degradation of gp130. Mol Cell Biol. 2008;28(15):4805-4818.
33. d'Azzo A, Bongiovanni A, Nastasi T. E3 ubiquitin ligases as regulators of membrane protein trafficking and degradation. Traffic. 2005;6(6):429-441.
34. Belouzard S, Rouille Y. Ubiquitylation of leptin receptor OB-Ra regulates its clathrin-mediated endocytosis. EMBO J. 2006;25(5):932-942. (Pubitemid 43372108)
35. Gorden P, Carpentier JL, Cohen S, Orci L. Epidermal growth factor: morphological demonstration of binding, internalization, and lysosomal association in human fibroblasts. Proc Natl Acad Sci U S A. 1978;75(10):5025- 5029.
36. Hanover JA, Beguinot L, Willingham MC, Pastan IH. Transit of receptors for epidermal growth factor and transferrin through clathrin-coated pits: analysis of the kinetics of receptor entry. J Biol Chem. 1985;260(29):15938- 15945.
37. van Kerkhof P, Sachse M, Klumperman J, Strous GJ. Growth hormone receptor ubiquitination coincides with recruitment to clathrin-coated membrane domains. J Biol Chem. 2001;276(6):3778-3784. (Pubitemid 37371453)
38. Hicke L. Ubiquitin-dependent internalization and down-regulation of plasma membrane proteins. FASEB J. 1997;11(14):1215-1226. (Pubitemid 27527885)
39. Miranda M, Sorkin A. Regulation of receptors and transporters by ubiquitination: new insights into surprisingly similar mechanisms. Mol Interv. 2007;7(3):157-167. (Pubitemid 47026726)
40. Rathinam C, Thien CB, Langdon WY, Gu H, Flavell RA. The E3 ubiquitin ligase c-Cbl restricts development and functions of hematopoietic stem cells. Genes Dev. 2008;22(8):992-997.
41. Caligiuri MA, Briesewitz R, Yu J, et al. Novel c-CBL and CBL-b ubiquitin ligase mutations in human acute myeloid leukemia. Blood. 2007;110(3):1022-1024. (Pubitemid 47267442)
42. Sargin B, Choudhary C, Crosetto N, et al. Flt3-dependent transformation by inactivating c-Cbl mutations in AML. Blood. 2007;110(3):1004-1012. (Pubitemid 47267440)